The U.S. Department of Health and Human Services is recommending to the U.S. Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under U.S. law, according to a report by Bloomberg on Wednesday. Currently cannabis is a Schedule I drug.
Cresco Labs Inc. CRLBF, +13.73% was rallying by 13.7%, Green Thumb Industries Inc. GTBIF, +19.51% was up by 17.6% and Trulieve Cannabis Corp. TCNNF, +17.28% was up by 15.6%. In a letter to the DEA seen by Bloomberg, Assistant Secretary for Health Rachel Levine cited a Food and Drug Administration review of the drug’s classification.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: